



NDA 020163/S-030

SUPPLEMENT APPROVAL

Baxter Healthcare Corp
Attention: Jennifer Masek-Little
25212 W. Illinois
Route 120
Round Lake, IL 60073

Dear Jennifer Masek-Little:

Please refer to your Supplemental New Drug Application (sNDA) dated and received January 15, 2020, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for DIANEAL PD-2 Peritoneal Dialysis Solution in ULTRABAG.

This “Changes Being Effected” supplemental new drug application provides for:

To harmonize the prescribing information across the three Baxter DIANEAL NDA’s (NDA 020183, NDA 020163 and NDA 017512).

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Megan Nguyen, Regulatory Business Process Manager, at Megan.Nguyen@fda.hhs.gov or (301) 796 - 7826.

Sincerely,

{See appended electronic signature page}

Gurpreet Gill Sangha, Ph.D.
Branch Chief, B3
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling



Gurpreet
Gill Sangha

Digitally signed by Gurpreet Gill Sangha
Date: 6/05/2023 10:30:35AM
GUID: 5135f2ad000117842392c50c36c7f28a